About: Funding of drugs: do vaccines warrant a different approach?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Funding of drugs: do vaccines warrant a different approach? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Funding of drugs: do vaccines warrant a different approach?
Creator	Beutels, Philippe Macintyre, Raina Scuffh, Paul
Source	Elsevier; Medline; PMC
abstract	Vaccines have features that require special consideration when assessing their cost-effectiveness. These features are related to herd immunity, quality-of-life losses in young children, parental care and work loss, time preference, uncertainty, eradication, macroeconomics, and tiered pricing. Advisory committees on public funding for vaccines, or for pharmaceuticals in general, should be knowledgable about these special features. We discuss key issues and difficulties in decision making for vaccines against rotavirus, human papillomavirus, varicella-zoster virus, influenza virus, and Streptococcus pneumoniae. We argue that guidelines for economic evaluation should be reconsidered generally to recommend (1) modelling options for the assessment of interventions against infectious diseases; (2) a wider perspective to account for impacts on third parties, if relevant; (3) a wider scope of costs than health-care system costs alone, if appropriate; and (4) alternative discounting techniques to explore social time preference over long periods.
has issue date	2008-10-20(xsd:dateTime)
bibo:doi	10.1016/s1473-3099(08)70258-5
bibo:pmid	18992409
has license	no-cc
sha1sum (hex)	20a583ee54e4ed8389e04fb951243da1a2286c54
schema:url	https://doi.org/10.1016/s1473-3099%2808%2970258-5
resource representing a document's title	Funding of drugs: do vaccines warrant a different approach?
has PubMed Central identifier	PMC7129011
has PubMed identifier	18992409
schema:publication	Lancet Infect Dis
resource representing a document's body	covid:20a583ee54e4ed8389e04fb951243da1a2286c54#body_text
is schema:about of	named entity 'alternative' named entity 'rotavirus' named entity 'general' named entity 'OPTIONS' named entity 'UNCERTAINTY' named entity 'RECOMMEND' named entity 'COSTS' named entity 'SOCIAL' named entity 'PHARMACEUTICALS' named entity 'ECONOMIC EVALUATION' named entity 'LOSS' named entity 'APPROPRIATE' named entity 'ERADICATION' named entity 'HEALTH' named entity 'TIME' named entity 'RELATED' named entity 'RELEVANT' named entity 'LONG' named entity 'TECHNIQUES' named entity 'WORK' named entity 'CARE SYSTEM' named entity 'YOUNG CHILDREN' named entity 'ASSESSMENT' named entity 'ROTAVIRUS' named entity 'VACCINES' named entity 'FUNDING' named entity 'DRUGS' named entity 'PERSONAL' named entity 'VIEW' named entity 'APPROACH' named entity 'VACCINES' named entity 'IMPACTS' named entity 'EFF' named entity 'STREPTOCOCCUS PNEUMONIAE' named entity 'ADVISORY COMMITTEES' named entity 'FEATURES' named entity 'INTERVENTIONS' named entity 'DECISION MAKING' named entity 'THEIR' named entity 'PERIODS' named entity 'KEY' named entity 'PRICING' named entity 'QUALITY-OF-LIFE' named entity 'PREFERENCE' named entity 'MACROECONOMICS' named entity 'HUMAN PAPILLOMAVIRUS' named entity '283' named entity 'ALTERNATIVE' named entity 'HAVE' named entity 'THIRD PARTIES' named entity 'PUBLIC FUNDING' named entity 'VARICELLA-ZOSTER VIRUS' named entity 'ABOUT' named entity 'HERD IMMUNITY' named entity 'COST' named entity 'SPECIAL' named entity '282' named entity 'SCOPE' named entity 'PARENTAL CARE' named entity 'DISCUSS' named entity 'THESE' named entity 'GUIDELINES ' named entity 'CONSIDERATION' named entity 'INFECTIOUS DISEASES' named entity 'VIRUS' named entity 'MODELLING' named entity 'ISSUES' named entity 'ASSESSING' named entity 'ACCOUNT' named entity 'PERSPECTIVE' named entity 'GENERAL' named entity 'features' named entity 'reconsidered' named entity 'herd immunity' named entity 'options' named entity 'vaccines' named entity 'scope' named entity 'time preference' named entity 'infectious diseases'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software